BioMarin Pharmaceuticals
BMRN
BMRN
575 hedge funds and large institutions have $18.9B invested in BioMarin Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 198 increasing their positions, 202 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
5% more funds holding
Funds holding: 547 → 575 (+28)
2% less repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 202
2.06% less ownership
Funds ownership: 100.43% → 98.37% (-2.1%)
Holders
575
Holding in Top 10
15
Calls
$185M
Puts
$117M
Top Buyers
| 1 | +$148M | |
| 2 | +$89.9M | |
| 3 | +$73.9M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$73.5M |
| 5 |
Bank of New York Mellon
New York
|
+$57.7M |
Top Sellers
| 1 | -$452M | |
| 2 | -$113M | |
| 3 | -$108M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$90.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$83.4M |